ArticleInflammopharmacology2025
Synergistic effects of melatonin and curcumin in ameliorating experimental autoimmune encephalomyelitis: insights into anti-inflammatory, antioxidant, and neuroprotective mechanisms.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diet for the prevention and treatment of Parkinson's disease.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundIn multiple sclerosis (MS) and its experimental model, experimental autoimmune encephalomyelitis (EAE), cellular inflammation and oxidative stress play key roles in disease pathogenesis. Melatonin and curcumin are natural compounds recognized for their neuroprotective properties. This study investigated their combined therapeutic potential in the EAE model.
methodsThirty female C57BL/6 mice were immunized with the MOG
resultsAll treatment groups exhibited reduced clinical severity and less leukocyte infiltration compared to untreated mice. The combined melatonin and curcumin therapy, however, produced superior outcomes. It significantly attenuated demyelination and promoted remyelination more effectively than single-agent treatments. This combination also resulted in the greatest reduction in blood-brain barrier permeability and the most substantial decrease in activated astrocytes and microglia. At the molecular level, the combined treatment significantly downregulated the pro-oxidant gene synthase while potently upregulating key antioxidant genes.
conclusionThe combined treatment of melatonin and curcumin significantly improved neurological function, reduced inflammation and oxidative stress, and enhanced remyelination in EAE mice. These findings suggest the therapeutic potential of these complementary agents, acting through a number of different pathophysiological pathways relevant to MS.
Indexed as
Identifiers
41207930What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.